雾化吸入对COPD并糖尿病大鼠血糖变化及死亡率的影响  

Glucose Changes and Mortality in Diabetic Rats with COPD of Inhaling Corticosteroids and Short-Acting β_2 Agonist

作　　者：陶绍华[1] 高凌云[1] 杨恂[1] 

机构地区：[1]成都大学附属医院,四川成都610081

出　　处：《现代临床医学》2014年第4期262-263,266,共3页Journal of Modern Clinical Medicine

摘　　要：目的:研究联合使用吸入性糖皮质激素及短效β2受体兴奋剂治疗慢性阻塞性肺疾病(COPD)并糖尿病大鼠,对大鼠血糖的变化以及死亡率的影响。方法:选取80只造模成功的COPD并糖尿病大鼠,随机分为A组、B组、C组、D组,每组各20只,分别给予单独吸入糖皮质激素治疗、单独吸入短效β2受体兴奋剂治疗、联合吸入糖皮质激素及短效β2受体兴奋剂治疗、生理盐水对照。各组大鼠雾化吸入治疗15 min/次,2次/d,疗程均为10 d。结果:联合吸入糖皮质激素及短效β2受体兴奋剂治疗的血糖控制情况与其他组比较无显著性差异(P>0.05),但联合吸入治疗组死亡率较其他组低(P<0.05)。结论:联合吸入糖皮质激素及短效β2受体兴奋剂治疗对COPD并糖尿病大鼠的血糖控制无影响,而且可以提高治疗水平,改善预后,降低死亡率。Objective：To study the glucose changes and mortality in diabetic rats with COPD of inhaling corticosteroids and short -acting β2 agonist .Methods：80 successful modeling diabetic rats with COPD were randomly divided into four groups of A ,B,C,D,n=20 in each group;there were the inhaled corticosteroids group, the inhaled short -acting β2 agonist group, the united inhaled glucocorticoids and short -acting β2 agonists group ,the saline control group;the atomization inhalation therapy in each group was for 15 minutes/time, 2 times/day;All groups were treated for 10 days.Results：The blood glucose control situation was no significant difference （ P〉0.05 ） between the united glucocorticoid and short -actingβ2 receptor agonist group and other groups , but the the mortality in united inhalation group was lower than in -other groups （ P 〈0.05 ） .Conclusion：The United inhaled glucocorticoids and short -acting β2 agonist in treatment of diabetes with COPD have no effect on blood sugar control , and can more effectively enhance therapeutic levels , improve their prognosis and reduce mortality .

关 键 词：慢性阻塞性肺疾病 糖尿病 糖皮质激素 短效β2 受体兴奋剂 

分 类 号：R587.1[医药卫生—内分泌]